Figures computed from official regulatory filings — .
Analysttarget 25.5 USD (+192%) · consensus 4.67/5 · 3 buy · 0 hold · 0 sell
Ownershipinsiders 15.55% · institutions 12.23% · short 1.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Akari Therapeutics Plc only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
31 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Gaslightwala Abizertrack record | Award | $62.5K | SEC |
| Farag Kameel D. | Award | $13K | SEC |
| Farag Kameel D. | Award | $13K | SEC |
| Patel Samir Rashmikant | ExerciseD (derivative) | $249.9K | SEC |
| Patel Samir Rashmikant | ExerciseD (derivative) | $93.7K | SEC |
| Patel Samir Rashmikant | Exercise | $2.3 | SEC |
| Patel Samir Rashmikant | Exercise | $6.2 | SEC |
| Patel Samir Rashmikant | ExerciseD (derivative) | $38.7K | SEC |
| Patel Samir Rashmikant | Exercise | $9.7K | SEC |
| Farag Kameel D. | Award | $13K | SEC |
| Farag Kameel D. | Award | $27.5K | SEC |
| Farag Kameel D. | Award | $12.5K | SEC |
| Farag Kameel D. | Award | $13K | SEC |
| Farag Kameel D. | Award | $13K | SEC |
| Gaslightwala Abizertrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Farag Kameel D. | Award | $13K | SEC |
| Gaslightwala Abizertrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Farag Kameel D. | Award | $13K | SEC |
| Neal James Rtrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | ClusterFirst in 12mo | SEC |
| Neal James Rtrack record | BuyD (derivative) | $989.2 | ClusterFirst in 12mo | SEC |
| Neal James Rtrack record | BuyD (derivative) | $1.2K | ClusterFirst in 12mo | SEC |
| Neal James Rtrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | ClusterFirst in 12mo | SEC |
| Gaslightwala Abizertrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | Cluster | SEC |
| Gaslightwala Abizertrack record | BuyD (derivative) | $309.3K | ClusterUnusual size | SEC |
| Patel Sandip Itrack record | BuyD (derivative) | $61.9K | ClusterFirst in 12mo | SEC |